
The FDA has moved to expand the existing approval of Janssen’s Spravato (esketamine) CIII nasal spray to include treatment of symptoms …
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions

